Eisai (OTCMKTS:ESALY) Cut to “Hold” at Zacks Investment Research

Eisai (OTCMKTS:ESALY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

Eisai stock traded down $12.50 during mid-day trading on Thursday, reaching $95.24. 325,210 shares of the stock traded hands, compared to its average volume of 27,841. The firm has a market capitalization of $28.25 billion, a PE ratio of 68.52, a PEG ratio of 7.36 and a beta of 0.32. The company has a quick ratio of 1.69, a current ratio of 2.02 and a debt-to-equity ratio of 0.07. Eisai has a 12-month low of $61.95 and a 12-month high of $129.79. The firm’s 50-day simple moving average is $68.92.

Eisai (OTCMKTS:ESALY) last posted its quarterly earnings data on Wednesday, May 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Eisai had a return on equity of 5.99% and a net margin of 6.56%. Equities research analysts expect that Eisai will post 1.42 EPS for the current fiscal year.

About Eisai

Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.

Featured Story: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.